Clinical trial
A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy
NCT05295589 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- June 30, 2022
- Completion date
- March 17, 2023
- Enrollment
- 0 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
platinum-refractory fallopian tube carcinoma, platinum-refractory ovarian carcinoma, platinum-refractory primary peritoneal carcinoma, recurrent fallopian tube endometrioid adenocarcinoma, recurrent fallopian tube high grade serous adenocarcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent ovarian high grade serous adenocarcinoma, recurrent platinum-resistant fallopian tube carcinoma, recurrent platinum-resistant ovarian carcinoma, recurrent platinum-resistant primary peritoneal carcinoma, recurrent primary peritoneal endometrioid adenocarcinoma, recurrent primary peritoneal high grade serous adenocarcinoma